Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950693 | 0.82 | LAP3 (0.72) | LAP3ANPEPRNPEPDNPEPKMT2A | |
| SCHEMBL7924570 | 0.77 | METAP2 (0.60) | LAP3ANPEPRNPEPDNPEPKMT2A | |
| SCHEMBL6961215 | 0.74 | CA12 (0.61) | KMT2APOLBCA12CA1CA2 | |
| SCHEMBL13073331 | 0.74 | CA12 (0.61) | KMT2APOLBCA12CA1CA2 | |
| SCHEMBL14861105 | 0.74 | CA12 (0.61) | KMT2APOLBCA12CA1CA2 | |
| SCHEMBL4814562 | 0.74 | LAP3 (0.49) | LAP3ANPEPRNPEPDNPEPKMT2A | |
| Hydrochloric Acid SCHEMBL7759019 | 0.73 | CA12 (0.60) | KMT2APOLBCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7206635 | 0.73 | CA12 (0.60) | KMT2APOLBCA12CA1CA2 | |
| SCHEMBL7361190 | 0.73 | LAP3 (0.67) | LAP3ANPEPRNPEPDNPEPKMT2A | |
| SCHEMBL14973840 | 0.72 | POLB (0.61) | LAP3ANPEPRNPEPDNPEPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | claimed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | claimed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | claimed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | claimed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-7358264-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | disclosed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | disclosed |
| US-6864290-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN, LLP (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | LAP3 286/4885ANPEP 63/4885RNPEP 97/4885 |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | LAP3 286/4885ANPEP 63/4885RNPEP 97/4885 |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | LAP3 321/4885ANPEP 84/4885RNPEP 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.